

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## HEALTH TECHNOLOGY APPRAISAL PROGRAMME

### Equality impact assessment – Guidance development

#### STA Targeted-release budesonide for treating primary IgA nephropathy (review of TA937)

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

#### Final draft guidance

(when no draft guidance was issued)

- |  |  |
|--|--|
| 1.   | Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
| No equality issues were identified during the scoping process. |  |

- |  |   |
|--|---|
| 2.   | Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
| One stakeholder noted population differences in the occurrence of IgA nephropathy, which disproportionately affects people living in deprived communities and those from ethnic minority groups – greater prevalence and more aggressive disease in people with East/Southeast Asian family background |   |
| The committee considered that differences in prevalence of a disease cannot normally be addressed in a technology appraisal recommendation.  |   |

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?

No other potential equality issues were identified by the committee.

4. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No.

5. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

No.

7. Have the committee's considerations of equality issues been described in the final draft guidance, and, if so, where?

Yes – in section 3.14.

**Approved by Associate Director (name):** ...Richard Diaz.....

**Date:** 19 Dec 2025

Technology appraisals: Guidance development

Equality impact assessment for the single technology appraisal of Targeted-release budesonide for treating primary IgA nephropathy (review of TA937)

Issue date: January 2026